


**ADDENDUM TO AUGUST 2009 MINUTES FOR  
DEPARTMENT OF DEFENSE  
PHARMACY AND THERAPEUTICS COMMITTEE  
RECOMMENDATIONS**

The evidence used to support the daily use of the Phosphodiesterase Type -5 (PDE-5) inhibitors for the off-label indication of preservation/restoration of erectile function after prostatectomy was published in February, May, and October 2008. This addendum makes retroactive the prior authorization for this indication to October 31, 2008.



---

Dr. Charles L. Rice  
Acting Director



---

(Date)